medigraphic.com
ISSN 1561-2929 (Print)

2016, Number 2

<< Back Next >>

RCAN 2016; 26 (2)

Sobre el comportamiento de los requerimientos de Eritropoyetina en los pacientes atendidos en un Programa de diálisis peritoneal domiciliaria

Language: Spanish
References: 12
Page: 365-369
PDF size: 273.73 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Kidney Disease Outcomes Quality Initiative. (2012). Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012; 2(Suppl):S279-S335.

  2. Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT, Pereira BJ. Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis 2001; 38:803-812.

  3. Nurko S. Anemia in chronic kidney disease: Causes, diagnosis, treatment. Cleveland J Med 2006;73:289-297.

  4. Eschbach JW. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-48.

  5. Santana Porbén S. La anemia asociada a la Enfermedad Renal Crónica. RCAN Rev Cubana Aliment Nutr 2014;24(2 Supl):S81-S89.

  6. Pérez-Oliva JF, Lagarde M, Herrera Valdés R. Eficacia del tratamiento con eritropoyetina recombinante humana cubana (Epocim) en pacientes anémicos hemodializados. Rev Habanera Ciencias Médicas 2004; 3(10):5-10.

  7. Pérez-Oliva JF, Lagarde M, Herrera Valdés R. Broad use of Cuban recombinant human erythropoietin (ior- EPOCIM) in dialysis patients at the Institute of Nephrology. MEDICC Review 2005;7(5):0-0. Disponible en: http://www.medicc.org/publications/me dicc_review/0505/cuban-medicalliterature- 2.html/. Fecha de última visita: 13 de Mayo del 2016.

  8. Pérez-Oliva JF, Casanovas-González ME, García I, Porrero PJ, Valenzuela CM, Hernández T, Lagarde M, Casanova Y, Avila Y, Vargas A, Bobillo H, Herrera R, López-Saura PA. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study. BMC Nephrol 2005;6(1):5. Disponible en: http://www.biomedcentral.com/1471- 2369/6/5/. Fecha de última visita: 13 de Mayo del 2016.

  9. Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004; 65:1864-9.

  10. Chandra M, Clemons G, Sahdev I, McVicar M, Bluestone P. Intraperitoneal production of erythropoietin with continuous ambulatory peritoneal dialysis. Pediatr Nephrol 1993;7;281-3.

  11. Snyder JJ, Foley RN, Gilbertson DT, Vonesh EF, Collins AJ. Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. J Am Soc Nephrol 2004;15:174-9.

  12. Coronel F, Herrero JA, Montenegro J, Fernandez C, Gandara A, Conesa J; et al. Erythropoietin requirements: A comparative multicenter study between peritoneal dialysis and hemodialysis. J Nephrol 2003;16:697-702.




2020     |     www.medigraphic.com